…and functional data for accurate genetic diagnosis in monogenic diabetes.…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 19 of 2459…emic rickets, familial haemophagocytic lymphohistiocytosis, and medium chain acyl-CoA dehydrogenase deficiency.SP110.1136/bmjmed-2025-001726.supp1Supplementary dataData sourc…
…k M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New Englan…
… high-dose corticosteroids, six sessions of plasmapheresis, and rituximab. Due to persistent pancytopenia with febrile neutropenia, empir…
…Abstract Objective To evaluate whether methylcobalamin could effectively and safely prevent hand-foot syndrome in pati…
…y were acute kidney injury (7.6%), pulmonary oedema (4.8%), and acute coronary syndrome (3.9%). These, alongside several other rarer complications, cou…
…ain characteristics of 2359 PWH enrolled in the Bictegravir and Dolutegravir SCOLTA cohortsAbstract P20 Table 2Reasons for 568 discontinuati…
…demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clini…
…herapy ( NCT02710253), and the Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malign…
…Introduction Bone metastases are a common and debilitating complication of advanced malignan…
…slowing lung function decline in lcSSc. In addition, a trial of tofacitinib with 40 (61%) lcSSc patients showed that this drug was more eff…